Carl Zeiss Meditec AG (LTS:0DHC) Other Financing: €-161 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0DHC Carl Zeiss Meditec AG LTS:0DHC
73 GF Score
Price €29.39
GF Value €63.62
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Other Financing?

Carl Zeiss Meditec AG LTS:0DHC +0.85% 73 Other Financing is €-161 Mil as of Mar. 2026. GuruFocus rates LTS:0DHC with a GF Score™ of 73/100 and a GF Value™ of €63.62 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Carl Zeiss Meditec AG's Other Financing for the six months ended in Mar. 2026 was €-27 Mil.

Carl Zeiss Meditec AG's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €-161 Mil.

Carl Zeiss Meditec AG Other Financing Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Other Financing Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -223.86 24.41 -59.69 1.02 -79.74

Carl Zeiss Meditec AG Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.75 363.27 54.36 -134.10 -27.24
LTS:0DHC
73GF Score
Carl Zeiss Meditec AG LTS:0DHC
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-161 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-161 Mil mean?
Carl Zeiss Meditec AG (LTS:0DHC) has a Other Financing of €-161 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's Other Financing too high?
Carl Zeiss Meditec AG's current Other Financing is €-161 Mil. Overall, Carl Zeiss Meditec AG has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Other Financing compare to ISRG and BDX?
Carl Zeiss Meditec AG's Other Financing of €-161 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Other Financing is €-161 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (LTS:0DHC) is currently considered Significantly Undervalued. The stock's GF Value™ is €63.62, compared to a current price of €29.39 — trading 53.8% below its estimated fair value. The current Other Financing is €-161 Mil. Carl Zeiss Meditec AG's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Carl Zeiss Meditec AG (LTS:0DHC), the current Other Financing is €-161 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (LTS:0DHC) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of €29.39 is trading 53.8% below its estimated GF Value™ of €63.62. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for LTS:0DHC:

  • Other Financing: €-161 Mil
  • GF Value™: €63.62 vs. price of €29.39 (53.8% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the LTS:0DHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
73GF Score

Get the complete analysis for LTS:0DHC

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.39
Price
€63.62
GF Value